Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers
The DOI matches its Crossref record.
Abstract
Tolcapone is a potent, reversible inhibitor of catechol O-methyltransferase (COMT) intended for use as an adjunct to levodopa therapy for Parkinson's disease (PD). Findings from the first pharmacokinetics/pharmacodynamics and tolerability studies of tolcapone in volunteers are reviewed. Following linear and dose-proportional pharmacokinetics, tolcapone is rapidly absorbed and eliminated after single- or multiple-dose (i.e., tid) administration. Onset of COMT inhibition is rapid, substantial, and reversible, and is not affected by the co-administration of levodopa/decarboxylase inhibitor (levodopa/DCI). When given together with levodopa/DCI, tolcapone increases the relative bioavailability and plasma elimination half-life of levodopa, without affecting its peak plasma concentration. This leads to more stable plasma levels of levodopa, and the formation of 3-O-methyldopa is effectively reduced. Tolcapone was well tolerated alone or in combination with levodopa/DCI, and the results indicated that the effective dose in patients with PD would be in the range of 50-400 mg tid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Jost, S. T., Kaldenbach, M., Antonini, A., Martinez‐Martin, P., Timmermann, L., Odin, P., Katzenschlager, R., Borgohain, R., Fasano, A., Stocchi, F., et al. (2023) · Movement Disorders · doi:10.1002/mds.29410 · Cited by 389
Tolcapone improves cognition and cortical information processing in normal human subjects
Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301227 · Cited by 242
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
Metadata
- Authors
- Jorga, K. M.
- Venue
- Neurology
- Published
- 1998-05
- Volume
- 50
- Issue
- 5_suppl_5
- Pages
- S31-8
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1985417541
- Cited by
- 37
- References
- 0
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers. https://app.cochat.ai/papers/10.1212/wnl.50.5_suppl_5.s31
- The paper
- Jorga, K. M. (1998). Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers. Neurology. https://doi.org/10.1212/wnl.50.5_suppl_5.s31
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.